Form 4: Bristol-Myers Squibb Executive Amanda Poole Ahn Reports Changes in Beneficial Ownership

EVP and Chief Human Resources Officer Amanda Poole Ahn reports transactions involving Bristol-Myers Squibb common stock and derivative securities, including vesting of market share units and performance shares.

Summary

• Amanda Poole Ahn, EVP and Chief Human Resources Officer at Bristol-Myers Squibb, filed a Form 4 detailing changes in her beneficial ownership of the company's securities.
• The reported transactions occurred on March 10, 2024, and include the vesting of market share units and performance shares, as well as the withholding of shares for tax payments.
• Ahn acquired 628 shares from vesting market share units granted on March 10, 2020, and 690 shares from units granted on March 10, 2021.
• She also received 4,140 performance shares earned under the 2021-2023 Long-Term Performance Award.
• Additionally, adjustments were made to the number of shares acquired upon vesting of market share units due to performance factors.
• Some market share units granted in 2022 and 2023 were cancelled because the minimum payout factor of 80% was not achieved.
• Following these transactions, Ahn directly owns 2,424 shares of common stock and indirectly owns 164,325 shares through the BMS Savings and Investment Program.
• She also holds derivative securities, including market share units and performance shares, which will convert into common stock in the future.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The document is a standard SEC filing detailing changes in beneficial ownership. While the vesting of shares is generally positive, the cancellation of some units due to unmet performance goals tempers the overall sentiment.

Positives

• The vesting of market share units and distribution of performance shares indicate that the company is meeting certain performance targets.
• The executive's continued holding of a significant number of shares and derivative securities suggests confidence in the company's future performance.

Negatives

• The cancellation of some market share units due to not meeting the minimum payout factor suggests that certain performance goals were not achieved.
• Shares were withheld for tax payments upon the vesting of awards, reducing the number of shares received.

Risks

• The value of the market share units and performance shares is dependent on the future stock price of Bristol-Myers Squibb.
• Changes in the company's performance or market conditions could affect the payout factor and the number of shares ultimately received.

Future Outlook

Twenty-five percent of the market share unit award will vest on each of the first, second, third and fourth anniversaries of the grant date.

Industry Context

Executive compensation and stock ownership are common practices in the pharmaceutical industry to align management's interests with those of shareholders.

Comparison to Industry Standards

• Stock awards and performance-based compensation are standard practice among large pharmaceutical companies such as Pfizer (PFE), Johnson & Johnson (JNJ), and Merck (MRK).
• These companies often use a mix of stock options, restricted stock units (RSUs), and performance shares to incentivize executives.
• The specific terms of these awards, such as vesting schedules and performance metrics, can vary widely depending on the company's compensation philosophy and strategic goals.
• Bristol-Myers Squibb's use of market share units and performance shares is consistent with industry trends in aligning executive compensation with shareholder value.

Stakeholder Impact

• The vesting of shares and distribution of performance shares could have a minor positive impact on shareholder sentiment.
• The executive's stock ownership aligns her interests with those of shareholders.

Key Dates